These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29102970)

  • 1. Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
    Mohan N; Chia YY; Goh GH; Ting E; Teo K; Yeo TT
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29102970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
    Elenkova A; Shabani R; Kalinov K; Zacharieva S
    Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of cabergoline in the treatment of macroprolactinoma].
    Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
    Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E; Maiter D; Donckier J
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
    Cawood TJ; Bridgman P; Hunter L; Cole D
    Intern Med J; 2009 Apr; 39(4):266-7. PubMed ID: 19402868
    [No Abstract]   [Full Text] [Related]  

  • 7. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
    Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinoma presenting as painful postganglionic Horner syndrome.
    Talkad AV; Kattah JC; Xu MY; Orth EH; Chang JY
    Neurology; 2004 Apr; 62(8):1440-1. PubMed ID: 15111696
    [No Abstract]   [Full Text] [Related]  

  • 10. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
    Colao A; Galderisi M; Di Sarno A; Pardo M; Gaccione M; D'Andrea M; Guerra E; Pivonello R; Lerro G; Lombardi G
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3777-84. PubMed ID: 18682513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.
    Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD
    Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary apoplexy associated with cabergoline therapy.
    Chng E; Dalan R
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Giant prolactinomas presenting as skull base tumors.
    Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
    Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
    Kurosaki M; Kambe A; Watanabe T; Fujii S; Ogawa T
    Neurol Res; 2015 Apr; 37(4):341-6. PubMed ID: 25376133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risks of medical treatment of prolactinoma.
    Castinetti F; Albarel F; Amodru V; Cuny T; Dufour H; Graillon T; Morange I; Brue T
    Ann Endocrinol (Paris); 2021 Feb; 82(1):15-19. PubMed ID: 33373604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.